Metabolix, Inc. Stock Nasdaq
Equities
US5910188821
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
Sales 2024 * | 1.2M 1.64M | Sales 2025 * | 2.6M 3.56M | Capitalization | 530K 725K |
---|---|---|---|---|---|
Net income 2024 * | -9M -12.31M | Net income 2025 * | -11M -15.04M | EV / Sales 2024 * | 0.44 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.2 x |
P/E ratio 2024 * |
-0.08
x | P/E ratio 2025 * |
-0.07
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
Latest transcript on Metabolix, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Oliver Peoples
FOU | Founder | 66 | 92-05-31 |
Charles Haaser
DFI | Director of Finance/CFO | 68 | 07-12-31 |
Kristi Snell
CTO | Chief Tech/Sci/R&D Officer | 56 | 96-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 67 | 06-09-30 | |
Richard Hamilton
BRD | Director/Board Member | 61 | 17-03-01 |
Oliver Peoples
FOU | Founder | 66 | 92-05-31 |
1st Jan change | Capi. | |
---|---|---|
+26.62% | 46.56B | |
+45.38% | 41.67B | |
+0.85% | 41.16B | |
+31.25% | 32.4B | |
+22.43% | 28.18B | |
-6.35% | 28.1B | |
+49.39% | 14.52B | |
+49.36% | 13.74B | |
+3.82% | 12.17B |